SS-31 (Elamipretide) dosing & administration
A revolutionary mitochondria-targeting peptide that works like a direct energy boost for your cells—binding to cardiolipin in your mitochondria to supercharge ATP production, reduce oxidative stress, and protect your cellular powerhouses from age-related decline [1].
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team
Dosing
How much do I take?
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
40 mg
Frequency
Once daily
Duration
12 weeks (extended in open-label to 36+ weeks)
Dose used in the phase 2/3 Barth syndrome trial and its open-label extension [6].
Timing
Best time to take
Morning injection is often preferred since SS-31 supports cellular energy production—aligning with your active hours makes sense [1]. However, timing is flexible based on your schedule.
With food?
SS-31 can be taken regardless of food timing. The peptide is absorbed efficiently whether you've eaten or not, so fit it into whatever routine works best for you.
If stacking
If combining with other peptides, inject at different sites. SS-31 pairs well with NAD+ precursors like NMN for comprehensive mitochondrial support [15]. Space different peptide injections at least 30 minutes apart.
Adjusting your dose
Increase if
- You've completed 2+ weeks at starting dose with no issues
- You're following a research protocol calling for standard doses
- Your healthcare provider recommends advancement based on your goals
Decrease if
- You experience persistent injection site reactions beyond 48 hours
- Headaches or nausea don't improve after the first week
- Any unexpected or uncomfortable side effects arise
- You have any kidney function concerns
Signs of right dose
- Improved energy levels, especially sustained throughout the day
- Better exercise tolerance or recovery
- No significant injection site issues
- General sense of vitality maintained or enhanced
Administration
How do I use it?
Reconstitution
What you need
Example
If you have a 50 mg vial and add 2.5 mL of bacteriostatic water, you get a concentration of 20 mg/mL. So 0.5 mL (50 units on an insulin syringe) equals 10 mg of SS-31, and 2 mL (200 units) equals the full 40 mg dose.
For a 40 mg dose at 20 mg/mL concentration: draw 2 mL. For a 20 mg dose: draw 1 mL. For a 10 mg dose: draw 0.5 mL (50 units).
Injection
Route
Subcutaneous injection (just under the skin)—the standard method used in clinical trials with approximately 92% bioavailability
Best sites
Technique
- 01Wash your hands thoroughly with soap and water
- 02Clean the injection site with an alcohol swab and let it air dry completely
- 03Pinch about an inch of skin to create a fold of fatty tissue
- 04Insert the needle at a 45-90 degree angle (45 if lean, 90 if you have more subcutaneous tissue)
- 05Inject the solution slowly and steadily
- 06Wait 5-10 seconds before withdrawing the needle
- 07Apply light pressure with a clean swab if needed—do not rub
Storage
Before reconstitution
Store lyophilized SS-31 powder in the refrigerator at 36-46°F (2-8°C). For long-term storage beyond 3 months, keep frozen at -4°F (-20°C) or below. Keep in the original sealed vial away from light. Properly stored powder remains stable for up to 2 years frozen.
After reconstitution
Refrigerate reconstituted SS-31 at 36-46°F (2-8°C). Never freeze once reconstituted—freezing destroys peptide structure. Protect from light and use within 28 days of reconstitution.
Signs of degradation — discard the vial
Sample daily schedule
Morning (6-9 AM)
20-40 mg depending on protocol injection
Site: Rotate between abdomen, thigh, and arm
Morning dosing aligns with natural circadian energy needs. SS-31 reaches peak blood levels within 30-60 minutes. Inject consistently at the same time each day for best results. Rotate injection sites to prevent tissue irritation.
Safety
Is it safe?
Safety profile
SS-31 (elamipretide) has demonstrated a favorable safety profile across multiple clinical trials, including studies lasting up to 24 weeks [10]. The most common adverse events are mild injection site reactions [6][10]. In September 2025, elamipretide received FDA approval for Barth syndrome, validating its safety in that population [8][9]. Most side effects are mild to moderate and typically resolve with continued use or dose adjustment.
Safety data comes from Phase 1-3 clinical trials in various populations including heart failure patients, those with primary mitochondrial myopathies, and Barth syndrome patients [1][6]. While generally well-tolerated, long-term safety beyond 6 months requires more data in healthy populations. Always work with a healthcare provider when using this compound.
Common side effects
Experienced by some users
Injection site reactions
Redness, swelling, itching, or mild pain at the injection site is the most frequently reported side effect in clinical trials [7][10]. This is your skin's normal reaction to the injection process.
Management: Rotate injection sites between abdomen, thigh, and arm. A cool compress can help reduce discomfort. Reactions typically fade within 24-48 hours.
Headache
Some users experience mild to moderate headaches, particularly during the first week of use [7]. This may be related to changes in cellular energy metabolism.
Management: Stay well-hydrated and consider over-the-counter pain relief if needed. Headaches usually resolve as your body adjusts within the first 1-2 weeks.
Fatigue
Paradoxically, some people feel tired initially even though SS-31 supports energy production. Your body may be recalibrating its energy systems.
Management: Rest as needed and ensure adequate sleep. This typically improves after the first week as mitochondrial function optimizes.
Nausea
Mild stomach upset or nausea can occur, particularly when starting treatment or at higher doses.
Management: Taking your injection with a small meal may help. If persistent, consider temporarily reducing your dose.
Less common
- Dizziness
- Flushing
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Any signs of allergic reaction—stop immediately and seek medical attention
- Injection site reactions that spread, worsen, or show signs of infection
- Persistent nausea, headaches, or dizziness that don't improve after 2 weeks
- Development of kidney-related symptoms (significant changes in urination, swelling)
- Any side effect that feels serious or significantly impacts your quality of life
- Your healthcare provider advises discontinuation
SS-31 (elamipretide) is FDA-approved only for Barth syndrome. For other uses, it remains a research compound. Never start, stop, or adjust your protocol without guidance from a qualified healthcare provider. This information is for educational purposes only and is not medical advice.
Interactions
With other peptides
- Epithalon - Potentially synergistic pairing—Epithalon targets telomeres while SS-31 targets mitochondria, addressing two major aging mechanisms simultaneously.
- BPC-157 - Can be combined for comprehensive cellular protection and healing support. Inject at different sites.
- MOTS-c - Both target mitochondrial function through different mechanisms. May have additive effects but combined use hasn't been extensively studied.
- GHK-Cu - Safe combination for multi-pathway anti-aging approach. Different mechanisms of action without known interactions.
With medications
- Nephrotoxic drugs (aminoglycosides, NSAIDs) - SS-31 is excreted by the kidneys. Combining with kidney-stressing medications may increase risk of renal issues. Consult your doctor.
- Diabetes medications (metformin, insulin) - Both may affect mitochondrial function or glucose metabolism. Monitor blood sugar more closely during SS-31 use.
- Blood thinners (warfarin, aspirin) - May increase bruising at injection sites. Not dangerous but worth monitoring. Inform your healthcare provider.
- Heart failure medications - SS-31 has been studied in heart failure patients alongside standard medications. Generally compatible but always inform your cardiologist.
With supplements
- CoQ10 (Ubiquinol) - Excellent synergy—both support mitochondrial electron transport chain function through complementary mechanisms.
- NAD+ precursors (NMN, NR) - Potentially beneficial combination for comprehensive mitochondrial support. NMN supports NAD+ levels while SS-31 protects mitochondrial structure.
- PQQ - May work synergistically to support mitochondrial biogenesis and function. Both target different aspects of mitochondrial health.
- Alpha-lipoic acid - Both have antioxidant properties. Safe combination that may provide enhanced mitochondrial protection.
- High-dose iron supplements - Iron can catalyze oxidative reactions in mitochondria. Avoid taking high-dose iron supplements simultaneously—space them out.
Published research
What the studies show
Tung C, Varzideh F, Farroni E · 2025
This comprehensive review confirmed SS-31's unique ability to selectively bind cardiolipin in mitochondria, stabilizing cristae structure, reducing oxidative stress, and enhancing ATP production. Clinical trials like PROGRESS-HF, TAZPOWER, and MMPOWER-3 demonstrate significant therapeutic potential across multiple conditions involving mitochondrial dysfunction.
Chavez JD, Tang X, Campbell MD · 2020
Using advanced chemical cross-linking and mass spectrometry, researchers mapped exactly which proteins SS-31 interacts with inside mitochondria. All the interacting proteins are known cardiolipin binders involved in either ATP production or metabolic processes—confirming SS-31's highly targeted mechanism of action.
Mitchell W, Tamucci JD, Ng EL · 2022
This study analyzed how SS-31's specific amino acid sequence affects its activity. The research showed SS-31 modulates membrane electrostatics and can permeate cells to target mitochondria. All tested peptide variants were pharmacologically active in restoring mitochondrial membrane potential and promoting cell survival under stress.
Gu Q, Wang Y, Zhang H · 2025
At 5 mg/kg daily, SS-31 significantly reduced lung fibrosis in mice by protecting mitochondrial structure and function. The peptide reduced oxidative stress markers, inflammatory factors (TNF-alpha, IL-1beta, IL-6), and improved overall lung tissue health—demonstrating its potential beyond cardiac applications.
Ravenscraft B, Lee DH, Dai H · 2025
SS-31 protected neurons from mitochondrial dysfunction and cell death in both laboratory and animal models of spinal cord injury. The peptide reduced cardiolipin loss, prevented neurite degeneration, and improved behavioral recovery—highlighting its neuroprotective potential.
Reid Thompson W, Hornby B, Manuel R, et al. · 2021
Cognitive Vitality (ADDF) · 2019
U.S. Food and Drug Administration · 2025
FDA prescribing information for FORZINITY (elamipretide), granted accelerated approval in September 2025 to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. The label lists injection site reactions as the most common adverse reactions and reports absolute bioavailability after subcutaneous injection of approximately 92%. Continued approval may depend on verification of clinical benefit in a confirmatory trial.
Stealth BioTherapeutics · 2025
Company announcement of the FDA's accelerated approval of elamipretide (FORZINITY) on September 19, 2025 for Barth syndrome. The announcement describes the product as the first approved mitochondria-targeted therapeutic and the first treatment option for Barth syndrome.
Karaa A, Bertini E, Carelli V · 2023
In this 24-week phase 3 trial, 218 adults with primary mitochondrial myopathy received 40 mg/day subcutaneous elamipretide or placebo. Elamipretide did not improve six-minute walk distance or total fatigue score compared with placebo. Most adverse events were mild or moderate, and injection site reactions were the only adverse events reported in more than 10% of treated participants.
Mitchell W, Ng EA, Tamucci JD · 2020
This biophysical study reports that SS-31 accumulates 1,000- to 5,000-fold at the inner mitochondrial membrane. Its binding to anionic lipids such as cardiolipin changes membrane surface electrostatics, which the authors identify as a key component of how the peptide works.
Ahmadpour ST, Maheo K, Servais S · 2020
This review states that cardiolipin is a mitochondria-specific phospholipid comprising about 20% of the inner mitochondrial membrane, and describes its role in organizing respiratory chain complexes and mitochondrial membrane structure.
Yoo Y, Yeon M, Yoon MS · 2025
This review reports that cardiolipin accounts for roughly 18% of inner mitochondrial membrane mass, that cardiolipin levels are reduced in aged skeletal muscle alongside impaired respiratory capacity and structural degradation, and that cardiolipin depletion disrupts cristae organization, lowers electron transport chain efficiency and increases reactive oxygen species production.
Li Y, Berliocchi L, Li Z · 2023
This review treats mitochondrial dysfunction as one of the established hallmarks of aging and examines how it interacts with the other hallmarks, describing it as one of the most important drivers of cellular aging.
Whitson JA, Bitto A, Zhang H · 2020
In aged mice, SS-31 improved diastolic heart function while nicotinamide mononucleotide (NMN) improved systolic function at high workload. The combination produced both effects and raised steady-state NAD(H) levels more than either drug alone, leading the authors to conclude that combined treatment may be more effective for age-related cardiac dysfunction than either agent given alone.
Smuder AJ, Roberts BM, Wiggs MP · 2020
In mice bearing colon-26 tumors, daily SS-31 preserved body weight and muscle weights, prevented atrophy of type I and type IIa muscle fibers, and prevented the loss of diaphragm and limb muscle function seen in untreated tumor-bearing mice, alongside reduced mitochondrial reactive oxygen species production.
Head to head
SS-31 (Elamipretide) compared
Want the full picture?
The complete SS-31 (Elamipretide) research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.